Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …

Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …

Single nucleotide polymorphism (SNP) is the most abundant molecular marker associated
with many physiologic and pathologic phenotypes. An isothermal, accurate and cost …

Background Clopidogrel has provided beneficial effects in acute coronary syndrome and
percutaneous coronary intervention. Different polymorphisms have been associated with …

This multicenter clinical study was aimed at conducting a targeted pharmacogenomic
association analysis of residual on‐clopidogrel platelet reactivity in 474 Caribbean Hispanic …

Introduction The effects of the ABCB1 C3435T genetic polymorphism on clopidogrel
responses are conflicting and inconclusive especially in patients undergoing percutaneous …

Résumé Objectif Peu d'études ont cherché asavoir comment des modifications de la
pharmacogénomique et de la pharmacogénétique pouvaient affecter les traitements …

Purpose A high interindividual variability is observed in the pharmacokinetics of clopidogrel,
a widely used antiplatelet drug. In the present study, a joint parent-metabolite population …

Only limited data are available regarding the treatment of critically ill patients with
clopidogrel. This trial investigated the effects and the drug concentrations of the cytochrome …

To investigate the genotype frequencies of cytochrome P450, family2, subfamily C,
polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients …